FOXL2 and neoplasm: CIMP status was predicted using an established array-based marker panel of CIMP, including B3GAT2, FOXL2, KCNK13, RAB31, and SLIT1, that was shown to identify CIMP+ (CIMP-H or CIMP-L) tumours with 100% sensitivity and 95.5% specificity, with 2.4% misclassification [5].